NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,294 | -67.1% | 80,150 | -15.4% | 0.01% | -65.8% |
| Q2 2023 | $3,934 | -31.0% | 94,789 | 0.0% | 0.04% | -33.3% |
| Q1 2023 | $5,700 | -15.3% | 94,789 | +3.3% | 0.06% | -19.7% |
| Q4 2022 | $6,733 | -99.9% | 91,789 | 0.0% | 0.07% | -13.4% |
| Q3 2022 | $6,974,000 | -8.3% | 91,789 | 0.0% | 0.08% | +10.8% |
| Q1 2022 | $7,605,000 | +10.4% | 91,789 | 0.0% | 0.07% | +21.3% |
| Q4 2021 | $6,891,000 | -35.4% | 91,789 | 0.0% | 0.06% | -38.4% |
| Q3 2021 | $10,664,000 | -47.6% | 91,789 | 0.0% | 0.10% | -47.1% |
| Q2 2021 | $20,360,000 | +62.8% | 91,789 | -3.0% | 0.19% | +52.0% |
| Q1 2021 | $12,505,000 | -22.1% | 94,609 | +1.9% | 0.12% | -23.6% |
| Q4 2020 | $16,060,000 | +62.6% | 92,809 | +4.6% | 0.16% | +43.8% |
| Q3 2020 | $9,874,000 | +79.6% | 88,709 | -4.3% | 0.11% | +72.3% |
| Q2 2020 | $5,498,000 | -11.9% | 92,709 | 0.0% | 0.06% | -26.1% |
| Q1 2020 | $6,243,000 | – | 92,709 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |